NCT04340596View on ClinicalTrials.gov

Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

May 21, 2021

Primary Completion Date

June 30, 2026

Study Completion Date

December 30, 2026

Conditions
HIV Infection
Interventions
BIOLOGICAL

N-803 (IL-15 Superagonist)

Administered by subcutaneous (SQ) injection

BIOLOGICAL

VRC07-523LS

Administered by intravenous (IV) infusion

BIOLOGICAL

10-1074

Administered by intravenous (IV) infusion

Trial Locations (14)

10032

Columbia P&S CRS, New York

10065

Weill Cornell Uptown CRS (Site ID: 7803), New York

19104

Penn Therapeutics, CRS (Site ID: 6201), Philadelphia

20005

Whitman-Walker Institute, Inc. CRS (Site ID: 31791), Washington D.C.

27599

Chapel Hill CRS (Site ID: 3201), Chapel Hill

35222

Alabama CRS (Site ID# 31788), Birmingham

44106

Case Clinical Research Site, Cleveland

60611

Northwestern University CRS, Chicago

90035

UCLA CARE Center CRS, Los Angeles

92103

UCSD Antiviral Research Center CRS (Site ID: 701), San Diego

94110

University of California, San Fransisco HIV/AIDS CRS, San Francisco

02114

Massachusetts General Hospital CRS (MGH CRS) (Site ID: 101), Boston

63110-1010

Washington University Therapeutics (WT) CRS, St Louis

07103

New Jersey Medical School Clinical Research Center CRS [Site ID: 31786], Newark

Sponsors

Collaborators (1)

ImmunityBio, Inc.
All Listed Sponsors
collaborator

Rockefeller University

OTHER

collaborator

ImmunityBio, Inc.

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT04340596 - Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption | Biotech Hunter | Biotech Hunter